Related Experiment Video
Updated: Jun 13, 2026
06:32
Multiplex Immunohistochemical Analysis of the Spatial Immune Cell Landscape of the Tumor Microenvironment
Published on: August 18, 2023
Differential immunophenotypic analysis of dendritic cell tumours
Tomohiko Orii1, Hiroaki Takeda, Sumio Kawata
1Department of Pathological Diagnostics, Faculty of Medicine, Yamagata University, Yamagata, Japan.
Journal of Clinical Pathology
|May 5, 2010
Summary
This study compared dendritic cell (DC) tumor markers to aid diagnosis. Langerin, DC-SIGN, and DEC-205 help differentiate DC tumor types and malignancy.
Area of Science:
- Oncology
- Immunohistochemistry
- Pathology
Background:
- Dendritic cell (DC) tumors exhibit diverse phenotypic and biological characteristics.
- Accurate diagnosis of DC tumors is crucial for effective treatment and prognosis.
Purpose of the Study:
- To compare immunophenotypic profiles of DC-related and cell-cycle markers in DC tumors.
- To utilize these markers for the differential diagnosis of DC tumors.
Main Methods:
- Immunohistochemical analysis of 28 DC tumor tissue sections.
- Evaluation of DC-related markers (S-100, CD1a, Langerin, fascin, DEC-205, DC-SIGN) and cell-cycle markers (Ki-67, cyclins, p53).
Main Results:
- Langerhans cell histiocytosis (LCH) and Langerhans cell sarcoma (LCS) showed positivity for S-100, CD1a, Langerin, fascin, DEC-205, and DC-SIGN.
- Interdigitating dendritic cell sarcoma (IDCS) was positive for S-100 and fascin, but negative for Langerin.
- LCS and IDCS exhibited higher cell-cycle marker indices and p53 expression compared to LCH. LCS also had increased infiltrating CD123(+) and FOXP3(+) cells.
Conclusions:
- Langerin can distinguish Langerhans cell sarcoma (LCS) from Interdigitating dendritic cell sarcoma (IDCS).
- DC-SIGN and DEC-205 aid in identifying DC tumor cells.
- Cell-cycle associated markers assist in differentiating malignant from benign DC tumors.
